Selected research
Industry Growth & Trends
Global Therapeutic Cancer Vaccines Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Therapeutic Cancer Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Therapeutic Cancer Vaccines market include Merck, GlaxoSmithKline, Bayer, VAXIMM, Northwest Biotherapeutics, Moderna, Mayo Clinic, Avax Technologies and Asterias Biotherapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Therapeutic Cancer Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Therapeutic Cancer Vaccines market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Therapeutic Cancer Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Therapeutic Cancer Vaccines.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Therapeutic Cancer Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Therapeutic Cancer Vaccines Market by Company
Merck
GlaxoSmithKline
Bayer
VAXIMM
Northwest Biotherapeutics
Moderna
Mayo Clinic
Avax Technologies
Asterias Biotherapeutics
Antigenics
Therapeutic Cancer Vaccines Segment by Type
Non-specific and Cytokine Strategies
Antigen Vaccine
Whole Cell Vaccine
Others
Therapeutic Cancer Vaccines Segment by Application
Breast Cancer
Prostate Cancer
Brain Tumors
Cervical Cancer
Lung Cancer
Bladder Cancer
Others
Therapeutic Cancer Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Cancer Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Therapeutic Cancer Vaccines companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Non-specific and Cytokine Strategies
- Antigen Vaccine
- Whole Cell Vaccine
- Others
Applications
- Breast Cancer
- Prostate Cancer
- Brain Tumors
- Cervical Cancer
- Lung Cancer
- Bladder Cancer
- Others
Companies covered
- Merck
- GlaxoSmithKline
- Bayer
- VAXIMM
- Northwest Biotherapeutics
- Moderna
- Mayo Clinic
- Avax Technologies
- Asterias Biotherapeutics
- Antigenics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Therapeutic Cancer Vaccines Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Therapeutic Cancer Vaccines Market Size by Region (2021-2032)
- 1.4.1 Global Therapeutic Cancer Vaccines Market Size by Region (2021-2026)
- 1.4.2 Global Therapeutic Cancer Vaccines Market Size by Region (2027-2032)
- 1.5 Key Regions Therapeutic Cancer Vaccines Market Size (2021-2032)
- 1.5.1 North America Therapeutic Cancer Vaccines Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Therapeutic Cancer Vaccines Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Therapeutic Cancer Vaccines Market Size Growth Rate (2021-2032)
- 1.5.4 South America Therapeutic Cancer Vaccines Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Therapeutic Cancer Vaccines Market Size Growth Rate (2021-2032)
2 Therapeutic Cancer Vaccines Market by Type
- 2.1 Type Introduction
- 2.1.1 Non-specific and Cytokine Strategies
- 2.1.2 Antigen Vaccine
- 2.1.3 Whole Cell Vaccine
- 2.1.4 Others
- 2.2 Global Therapeutic Cancer Vaccines Market Size by Type
- 2.2.1 Global Therapeutic Cancer Vaccines Market Size Overview by Type (2021-2032)
- 2.2.2 Global Therapeutic Cancer Vaccines Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Therapeutic Cancer Vaccines Market Size Forecasted by Type (2027-2032)
- 2.3 Global Therapeutic Cancer Vaccines Market Size by Regions
- 2.3.1 North America Therapeutic Cancer Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Therapeutic Cancer Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Therapeutic Cancer Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Therapeutic Cancer Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Therapeutic Cancer Vaccines Market Size Breakdown by Type (2021-2026)
3 Therapeutic Cancer Vaccines Market by Application
- 3.1 Type Introduction
- 3.1.1 Breast Cancer
- 3.1.2 Prostate Cancer
- 3.1.3 Brain Tumors
- 3.1.4 Cervical Cancer
- 3.1.5 Lung Cancer
- 3.1.6 Bladder Cancer
- 3.1.7 Others
- 3.2 Global Therapeutic Cancer Vaccines Market Size by Application
- 3.2.1 Global Therapeutic Cancer Vaccines Market Size Overview by Application (2021-2032)
- 3.2.2 Global Therapeutic Cancer Vaccines Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Therapeutic Cancer Vaccines Market Size Forecasted by Application (2027-2032)
- 3.3 Global Therapeutic Cancer Vaccines Market Size by Regions
- 3.3.1 North America Therapeutic Cancer Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Therapeutic Cancer Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Therapeutic Cancer Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Therapeutic Cancer Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Therapeutic Cancer Vaccines Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Therapeutic Cancer Vaccines Industry Trends
- 4.2 Therapeutic Cancer Vaccines Industry Drivers
- 4.3 Therapeutic Cancer Vaccines Industry Opportunities and Challenges
- 4.4 Therapeutic Cancer Vaccines Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Therapeutic Cancer Vaccines Revenue (2021-2026)
- 5.2 Global Therapeutic Cancer Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Therapeutic Cancer Vaccines Key Company Headquarters & Area Served
- 5.4 Global Therapeutic Cancer Vaccines Company, Product Type & Application
- 5.5 Global Therapeutic Cancer Vaccines Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Therapeutic Cancer Vaccines Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Therapeutic Cancer Vaccines Players Market Share by Revenue in 2025
- 5.6.3 2025 Therapeutic Cancer Vaccines Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Merck Therapeutic Cancer Vaccines Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 GlaxoSmithKline
- 6.2.1 GlaxoSmithKline Company Information
- 6.2.2 GlaxoSmithKline Business Overview
- 6.2.3 GlaxoSmithKline Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio
- 6.2.5 GlaxoSmithKline Recent Developments
- 6.3 Bayer
- 6.3.1 Bayer Company Information
- 6.3.2 Bayer Business Overview
- 6.3.3 Bayer Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Bayer Therapeutic Cancer Vaccines Product Portfolio
- 6.3.5 Bayer Recent Developments
- 6.4 VAXIMM
- 6.4.1 VAXIMM Company Information
- 6.4.2 VAXIMM Business Overview
- 6.4.3 VAXIMM Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 VAXIMM Therapeutic Cancer Vaccines Product Portfolio
- 6.4.5 VAXIMM Recent Developments
- 6.5 Northwest Biotherapeutics
- 6.5.1 Northwest Biotherapeutics Company Information
- 6.5.2 Northwest Biotherapeutics Business Overview
- 6.5.3 Northwest Biotherapeutics Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
- 6.5.5 Northwest Biotherapeutics Recent Developments
- 6.6 Moderna
- 6.6.1 Moderna Company Information
- 6.6.2 Moderna Business Overview
- 6.6.3 Moderna Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Moderna Therapeutic Cancer Vaccines Product Portfolio
- 6.6.5 Moderna Recent Developments
- 6.7 Mayo Clinic
- 6.7.1 Mayo Clinic Company Information
- 6.7.2 Mayo Clinic Business Overview
- 6.7.3 Mayo Clinic Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio
- 6.7.5 Mayo Clinic Recent Developments
- 6.8 Avax Technologies
- 6.8.1 Avax Technologies Company Information
- 6.8.2 Avax Technologies Business Overview
- 6.8.3 Avax Technologies Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Avax Technologies Therapeutic Cancer Vaccines Product Portfolio
- 6.8.5 Avax Technologies Recent Developments
- 6.9 Asterias Biotherapeutics
- 6.9.1 Asterias Biotherapeutics Company Information
- 6.9.2 Asterias Biotherapeutics Business Overview
- 6.9.3 Asterias Biotherapeutics Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
- 6.9.5 Asterias Biotherapeutics Recent Developments
- 6.10 Antigenics
- 6.10.1 Antigenics Company Information
- 6.10.2 Antigenics Business Overview
- 6.10.3 Antigenics Therapeutic Cancer Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Antigenics Therapeutic Cancer Vaccines Product Portfolio
- 6.10.5 Antigenics Recent Developments
7 North America
- 7.1 North America Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 7.3 North America Therapeutic Cancer Vaccines Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 8.3 Europe Therapeutic Cancer Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Therapeutic Cancer Vaccines Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 10.3 South America Therapeutic Cancer Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Therapeutic Cancer Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Therapeutic Cancer Vaccines Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Therapeutic Cancer Vaccines Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst